Yes, it "inefficiency" is the same for patients treated with hemodialysis or peritoneal dialysis.

AURORA was conclusive. 5 years and ZERO benefit in cardiac endpoints or mortality rosuvastatin versus placebo. Those were hemodialysis patients, see answer above, and there no studies contradiction the total failure demostrated in AURORA.

NEJM Aprin 2, 2009.

Only lipid med proven of benefit in RCT in CKD patients is Vytorin, meaning simvastatin plus ezetimibe, (in SHARP) but, there was no benefit in those with end stage renal disease on dialysis

All RCT with antilipemic agents (atorvastatin, rosuvastatin, and simvastain- ezetimibe combo) showed a similar RRR of about 10% in CV end points but did not reach statistical significance (neither atorvastatin or rosuvastatin nor simva-ezetimibe combo in the subgroup of ESRD from SHARP). However subgroup analysis fron statin RCT and SHARP shows benefit in earlier stages of CRF.

Therefore, the benefit may be decreasing with progressive RF and is likely to be minimal, if any in ESRD.

Unfortunately recent american guidelines on CV prevention do not pay an adequate attention to CRF as a markr of Increased CV risk and many pacients with earlier stages of RF will miss a potencial effective treatment. Whether a statin or a statin- ezetimibe combo is better remainsvto be elucidated.

I agree with previous statements. However, recent ACC/AHA 2013 guidelines clearly state that patient in renal replacement therapy do not benefit from statin treatment, as shown in several trials including 4D, AURORA, SHARP. One of the reasons if we look at the AURORA trial is that hsCRP reduction was much lower compared to what was obtained in JUPITER despite having the expected LDL reduction.

I agree with most of the points mentioned in the previous replies, but anyone knows specific data for CAPD? (peritoneal dialysis). CAPD and hemodialysis (HD) are quite different in the degree of systemic inflammation that generate and lack of efficacy in cardiovascular prevention for HD could mask a benefit in the case of CAPD.

Please find attached the statement from ASCO on the benefit of statins for terminally ill